Skip to content

Efficacy and safety of Angelica and Safflower Spot Removal Essence for Melasma: A clinical trial

Efficacy and safety of Angelica and Safflower Spot Removal Essence for Melasma: A clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000284
Enrollment
Unknown
Registered
2024-08-22
Start date
2022-09-01
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma

Interventions

Controlled group:Blank essence without traditional Chinese medicine solution
Intervention group:Angelica and Safflower Spot Removal Essence

Sponsors

Beijing Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Ages between 18 to 60 years old; 2) Meeting the Western medical diagnostic criteria for melasma; 3) Meeting the traditional Chinese medicine diagnostic criteria for the syndrome of Qi stagnation and blood stasis in melasma; 4) Have not undergone any related treatments for melasma in the past 3 months (such as oral administration of tranexamic acid, glycyrrhizic acid, vitamin C, vitamin E, glutathione, blood-activating and stasis-eliminating drugs, etc.; external use of skincare products containing whitening ingredients like tranexamic acid, arbutin, etc.; external use of hydroquinone ointment, arbutin ointment, azelaic acid, etc.); 5) Signed the informed consent form, willing to participate voluntarily and accept treatment.

Exclusion criteria

Exclusion criteria: 1) Individuals with severe internal organ diseases such as heart, lung, liver, kidney, and gastrointestinal disorders, as well as those with significant illnesses like immune system deficiencies and patients with psychiatric disorders, cancer patients currently undergoing radiotherapy, chemotherapy, immunotherapy, etc.; 2) Pregnant and lactating women; 3) Individuals with skin in a state of severe allergy, pigmentation caused by other reasons, inflammatory reactions caused by external cosmetics, or inflammatory conditions such as acne, and those with facial wounds, ulcers, or herpes and other skin lesions; 4) Continuous use of corticosteroid medications, and vascular abnormalities caused by liver function abnormalities; 5) Individuals allergic to the ingredients of the red spot removing essence.

Design outcomes

Primary

MeasureTime frame
Melasma Area and Severity Index;

Secondary

MeasureTime frame
Physician's Global Assessment;Patient Self-Assessment;VISIA Analysis;

Countries

China

Contacts

Public ContactYuan-yuan Chen

Beijing Hospital of Integrated Traditional Chinese and Western Medicine

chenyuanyuan_001@163.com+86 138 1173 6949

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026